JT Stratford LLC Purchases New Stake in Insulet Co. (NASDAQ:PODD)

JT Stratford LLC bought a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 986 shares of the medical instruments supplier's stock, valued at approximately $257,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. acquired a new stake in shares of Insulet in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. bought a new stake in shares of Insulet in the fourth quarter valued at about $42,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares during the period. Assetmark Inc. raised its stake in shares of Insulet by 1,447.1% in the 4th quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Insulet by 117.3% in the 4th quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after buying an additional 149 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on PODD shares. Wall Street Zen cut shares of Insulet from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Barclays boosted their target price on Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. Oppenheimer raised their price objective on shares of Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a research report on Friday, May 9th. Citigroup restated a "buy" rating and set a $380.00 price objective (up previously from $320.00) on shares of Insulet in a research note on Thursday, May 22nd. Finally, Raymond James lifted their price objective on shares of Insulet from $328.00 to $360.00 and gave the company an "outperform" rating in a research note on Tuesday. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $309.88.

Insider Activity

In related news, SVP John W. Kapples sold 5,278 shares of the company's stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $318.47, for a total transaction of $1,680,884.66. Following the completion of the sale, the senior vice president now directly owns 23,180 shares of the company's stock, valued at approximately $7,382,134.60. This represents a 18.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the transaction, the director now owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company's stock.

Insulet Stock Performance

Insulet stock traded down $2.36 during mid-day trading on Wednesday, hitting $324.29. The company had a trading volume of 170,516 shares, compared to its average volume of 706,658. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company's fifty day moving average is $273.47 and its 200-day moving average is $270.65. Insulet Co. has a 12-month low of $171.61 and a 12-month high of $333.24. The company has a market capitalization of $22.82 billion, a price-to-earnings ratio of 55.97, a P/E/G ratio of 3.62 and a beta of 1.26.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping the consensus estimate of $0.81 by $0.21. The firm had revenue of $569.00 million during the quarter, compared to analysts' expectations of $543.20 million. Insulet had a return on equity of 24.46% and a net margin of 20.19%. During the same period in the previous year, the business earned $0.73 earnings per share. The firm's revenue for the quarter was up 28.8% on a year-over-year basis. Equities research analysts predict that Insulet Co. will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.